Synergy Pharmaceuticals Inc fka SGYPQ

[iDeVos]

That is ancient data. You need real time data. This world doesn’t stand still..

According to the latest 10-Q filing (click this link to view), as of 09/30/2018, they had
Total Assets: $83M
Total Liabilities: $179M
Net loss in Q3'18 was: $34M

Can you be more specific on the "real-time" data you're talking about? Are you saying that SGYP has burned a lot more than the typical $34M/quarter in the last Q4(2018) even they're no longer running any clinical trials?

My estimate is that the $195M received from BHC should be more than enough to cover all debts/liabilities, and the $83M in cash/assets should be more than enough for covering all operating/legal expenses in the last 4 months, and after 03/05/2019 SGYP should still have over $50M value in asset and zero debt while retaining their core GI platform (uroguanylin).

Please back up with real data rather than just making those baseless/unsubstantial claims.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1347613/000134761318000032/sgyp-20180930.htm